OPKO Health (NASDAQ:OPK – Get Rating) had its price objective lowered by Piper Sandler from $5.00 to $4.00 in a report published on Friday, Stock Target Advisor reports. The firm currently has an overweight rating on the biotechnology company’s stock.
OPKO Health Price Performance
NASDAQ OPK opened at $2.28 on Friday. OPKO Health has a one year low of $2.15 and a one year high of $5.25. The stock’s 50 day simple moving average is $2.62 and its 200 day simple moving average is $3.00. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.12 and a current ratio of 2.44.
OPKO Health (NASDAQ:OPK – Get Rating) last announced its quarterly earnings data on Thursday, August 4th. The biotechnology company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.12). The firm had revenue of $309.90 million during the quarter, compared to the consensus estimate of $326.87 million. OPKO Health had a negative net margin of 14.18% and a negative return on equity of 7.76%. The firm’s quarterly revenue was down 30.0% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.03) earnings per share. Sell-side analysts anticipate that OPKO Health will post -0.22 EPS for the current fiscal year.
Insider Buying and Selling at OPKO Health
Institutional Trading of OPKO Health
Hedge funds have recently added to or reduced their stakes in the business. Cornerstone Advisory LLC bought a new position in OPKO Health during the 4th quarter worth about $29,000. Aigen Investment Management LP bought a new position in OPKO Health during the 2nd quarter worth about $29,000. Humankind Investments LLC bought a new position in OPKO Health during the 1st quarter worth about $37,000. Guggenheim Capital LLC bought a new position in OPKO Health during the 1st quarter worth about $38,000. Finally, Point72 Hong Kong Ltd bought a new position in OPKO Health during the 1st quarter worth about $39,000. Institutional investors and hedge funds own 27.83% of the company’s stock.
OPKO Health Company Profile
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services.
- Get a free copy of the StockNews.com research report on OPKO Health (OPK)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.